These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 17220962)

  • 1. Molecule of the Month: Conivaptan hydrochloride.
    Drug News Perspect; 2006 Nov; 19(9):574. PubMed ID: 17220962
    [No Abstract]   [Full Text] [Related]  

  • 2. Conivaptan Yamanouchi.
    Doggrell SA
    Curr Opin Investig Drugs; 2005 Mar; 6(3):317-26. PubMed ID: 15816509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Disorders of body water regulation and the therapy using diuretics].
    Orita Y; Nakahama H
    Nihon Naika Gakkai Zasshi; 1997 Sep; 86(9):1660-4. PubMed ID: 9410979
    [No Abstract]   [Full Text] [Related]  

  • 4. Conivaptan: promise of treatment in heart failure.
    Hoque MZ; Arumugham P; Huda N; Verma N; Afiniwala M; Karia DH
    Expert Opin Pharmacother; 2009 Sep; 10(13):2161-9. PubMed ID: 19663609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
    Mao ZL; Stalker D; Keirns J
    Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conivaptan (Vaprisol) for hyponatremia.
    Med Lett Drugs Ther; 2006 Jun; 48(1237):51-2. PubMed ID: 16785851
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaptans and the treatment of water-retaining disorders.
    Quittnat F; Gross P
    Semin Nephrol; 2006 May; 26(3):234-43. PubMed ID: 16713496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia.
    Zeltser D; Rosansky S; van Rensburg H; Verbalis JG; Smith N;
    Am J Nephrol; 2007; 27(5):447-57. PubMed ID: 17664863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolvaptan and hyponatremia in a patient with cirrhosis.
    Boyer TD
    Hepatology; 2010 Feb; 51(2):699-702. PubMed ID: 20101750
    [No Abstract]   [Full Text] [Related]  

  • 10. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T; Fujiki H; Yamamura Y; Nakamura S; Mori T
    Cardiovasc Drug Rev; 2007; 25(1):1-13. PubMed ID: 17445084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conivaptan for treatment of hyponatremia in neurologic and neurosurgical adults.
    Buckley MS; Patel SA; Hattrup AE; Kazem NH; Jacobs SC; Culver MA
    Ann Pharmacother; 2013 Sep; 47(9):1194-200. PubMed ID: 24259735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The vaptans: just landed. But how was the trip?
    Gross P
    Nephrol Dial Transplant; 2010 May; 25(5):1367-8. PubMed ID: 20200008
    [No Abstract]   [Full Text] [Related]  

  • 13. The vaptans ante portas: a status report.
    Gross P; Marczewski T; Herbrig K
    Nephrol Dial Transplant; 2009 May; 24(5):1371-3. PubMed ID: 19218537
    [No Abstract]   [Full Text] [Related]  

  • 14. New drugs for hyponatraemia.
    Amin A; Meeran K
    BMJ; 2010 Nov; 341():c6219. PubMed ID: 21078752
    [No Abstract]   [Full Text] [Related]  

  • 15. Tolvaptan (Samsca) for hyponatremia.
    Med Lett Drugs Ther; 2009 Nov; 51(1326):95-6. PubMed ID: 20224525
    [No Abstract]   [Full Text] [Related]  

  • 16. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP; Balk RA
    Clin Ther; 2007 Feb; 29(2):211-29. PubMed ID: 17472815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac function and heart failure.
    Wagoner LE; Starling RC; O'Connor CM
    J Am Coll Cardiol; 2006 Jun; 47(11 Suppl):D18-22. PubMed ID: 16750716
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to a bolus of conivaptan in patients with acute hyponatremia after brain injury.
    Human T; Onuoha A; Diringer M; Dhar R
    J Crit Care; 2012 Dec; 27(6):745.e1-5. PubMed ID: 22520494
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extreme correction of hyponatremia in a patient treated with intravenous conivaptan.
    Sughrue ME; McDermott M; Blevins LS
    J Clin Neurosci; 2010 Oct; 17(10):1331-4. PubMed ID: 20594854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of oral vasopressin V2 receptor antagonist for hyponatremia in acute brain injury.
    Jeon SB; Choi HA; Lesch C; Kim MC; Badjatia N; Claassen J; Mayer SA; Lee K
    Eur Neurol; 2013; 70(3-4):142-8. PubMed ID: 23887035
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.